Dalian Zhen-Ao Bio-Tech Co., Ltd.   Report issue

For profit Phase 2 Phase 4
Founded: Dalian China (1996)

Organization Overview

First Clinical Trial
2016
NCT02989012
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Dalian Zhen-Ao Bio-Tech Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

cardiomyopeptidin (2 trials)

Drugs in Phase 2 Trials (2)

ganmaokangning (1 trial)

oseltamivir (tamiflu) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ischemia (Phase 4)

Reperfusion Injury (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3